Novel Ebola Vaccine Provides Sustained Antibody Response One Year After Administration

DISEASE-SPECIFIC TOPICS

Novel Ebola Vaccine Provides Sustained Antibody Response One Year After Administration

JUN 22, 2017 | BRIAN P. DUNLEAVY

The 2014 Ebola virus outbreak in western Africa—and the media-fueled global panic that ensued—highlighted the need for a viable vaccine against the disease.
 

Now, research suggests such a vaccine may be in the pipeline; arguably welcome news in light of the recent 2017 Ebola outbreak in the Democratic Republic of Congo.

Novel Ebola Vaccine Provides Sustained Antibody Response One Year After Administration

  

Novel Ebola Vaccine Provides Sustained Antibody Response One Year After Adm... The results of a recent Phase IB study show that the novel Ebola vaccine, V920, was well-tolerated and “stimulat...

Africa Center for Clin Gov Research & Patient Safety

@ HRI West Africa Group - HRI WA

Consultants in Clinical Governance Implementation

Publisher: Health and Medical Journals 

8 Amaku Street Housing Estate, Calabar
Cross River State, Nigeria

Phone No. +234 (0) 8063600642

Visit Website: www.hriwestafrica.com
E-mail: hriwestafrica@gmail.com